8 Weeks SEF Chemotherapy® to Take Place of
6-9 Months "Adjuvant" Chemo-radiotherapy
Published data from the United States National Cancer Institute (1) show that more than half of “early” breast cancer patients, stage 3, eventually die despite undergoing six months of grueling toxic adjuvant chemo-radiotherapy after a lumpectomy. The reason is that conventional chemotherapy is incomplete and fails to eradicate every cancer cell in the body.
On the other hand, the newer Side Effect-free (SEF) Chemotherapy® has been proven to be more thorough in eradicating all cancer cells. Where conventional chemotherapy fails, SEF Chemo® has induced long term remissions in patients whose cancer has spread to distant organs. The longest such survivor is a breast cancer patient in stage 4 with liver metastasis who was treated with eight weeks of SEF Chemo® in 2005. She is now in her tenth year completely free of cancer. SEF Chemo® achieves strong responses in all types of cancer treated to date, while conventional chemo agents, particularly in stage 4 breast cancer, show response in only 19-32 per cent of cases and when they do respond, cancer returns to progression after only three to six months (2). Clearly, SEF Chemo® is far superior to conventional chemotherapy.
Dr. Kenneth Matsumura, the developer of SEF Chemo®, just approved the use of SEF Chemo® in stage 3 breast cancer patients with strong lymph node spread.
Not only does conventional adjuvant chemo-radiotherapy not work very well, many women refused adjuvant therapy due to the horrible side effects — nausea, vomiting, and diarrhea are common. The chance of hair loss is high and when it occurs it is emotionally devastating. Radiation causes breasts to become hard and hypersensitive making many women avoid sex. Radiation exposes women to other cancers as well as to auto-immune diseases later in their lives. In conventional adjuvant therapy, it is common to purposely induce menopause in women.
Eight weeks SEF Chemotherapy® is virtually side effect-free and does not cause loss of hair from the therapy. SEF Chemo® does not induce menopause in women.
In conventional adjuvant therapy it is common for patients to undergo two months of toxic chemotherapy followed by eight weeks of five day-radiotherapy, and then another two months of chemotherapy. Many women cannot continue to work. Quite often, women's blood making marrow is so decimated that doctors have to use expensive marrow stimulators to restore blood counts. It is likely that permanent damage is done to the marrow that may affect patients in their senior years. Although the patients are told in the beginning that their therapy will last six months, in reality many patients end up receiving treatment for 9 months or more,while they put their lives on hold.
SEF Chemotherapy® patients often have the ability to continue working nearly full time while undergoing treatment and therapy is usually over in 8 to 10 weeks. Exceptions to this rule are uncommon.
1. National Cancer Institute — Stages of Breast Cancer, Stage IIIA-C.
2. Jones SE, Overmoyer EB, Budd GT, et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. Journal of Clinical Oncology. 2005;23:5542-5551.